New York, N.Y (USA) and Paris (France), November 6, 2018 – The prestigious Kreitchman PET Center of the Columbia University (New York) and Zionexa, a radiopharmaceutical company specialized in the development and commercialization of innovative molecular imaging companion diagnostics (CDx) for targeted therapies in oncology, have agreed to collaborate together on chemistry development and method validation for Zionexa’s new Positron Emission Tomography (PET) diagnostic drug, EstroTep, which is currently only approved in France for the characterization of estrogen receptor status in advanced breast cancer.
EstroTep1, a biomarker for targeted diagnostic for metastatic breast cancer
With more than 250,0002 new cases in 2017 in the United-States, breast cancer is the most common cancer among women. EstroTep is a new biomarker which is at the moment only approved for clinical use in France for identification of estrogen receptor status in patients with metastatic breast cancer. Zionexa is currently in the process of getting the product FDA cleared in the United States.
1 EstroTEP is NOT FDA cleared for use in the US and is only to be used in a physician sponsored clinical trial. For French prescribing information please contact firstname.lastname@example.org
2 American Cancer Society. Breast Cancer Fact and Figures 2017-2018. Atlanta: American Cancer Society, Inc. 2017.